A version of a drug mixed by a pharmacy rather than produced by the original manufacturer. Compounded semaglutide and tirzepatide became widely sold during the 2022–2025 shortages, but that exception largely ended once the shortages were declared over, followed by a major FDA enforcement wave in 2026. Compounded drugs are not FDA-approved, and quality depends heavily on the pharmacy — which is why we score providers partly on sourcing.
Related terms: 503A pharmacy · 503B outsourcing facility · Salt form (semaglutide sodium / acetate) · FDA drug shortage list